Patient-derived organoids in renal cell carcinoma: A review of methodologies and applications
Lab-grown patient tumors rapidly predict which drugs work best, accelerating personalized cancer medicine despite remaining technical challenges.
This review summarizes approaches for generating patient-derived organoids (PDOs) from renal cell carcinoma, covering Matrigel, ALI, and microfluidic systems, with applications in drug screening, tumor biology, and personalized therapy. PDOs are identified as a transformative tool for precision oncology despite challenges in standardization and microenvironment replication.
What the study was
- Study design
- Narrative review
- Population
- Renal cell carcinoma patients
- Category
- Drug Development
- Maturity
- Exploratory
- Journal
- Urologic Oncology
Why it surfaced
Review of PDO methodology in RCC — relevant to precision oncology but no new clinical data; design quality 0 for review.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.